Shortages of some injectable cancer drugs have created an opening for dangerous unapproved versions of Roche Holding AG’s Herceptin and Amgen Inc.’s Neupogen to be sold to clinics and other health-care providers, the U.S. said.
http://bloom.bg/w0KVKD
Printer-Friendly Version